Cellegy Cellegesic Receives FDA “Not Approvable” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Issues relate to pivotal studies for Cellegesic, even though the company conducted a third Phase III trial under a special protocol agreement with FDA. The letter “raised several issues that were not part of the agreed upon approval criteria,” Cellegy claims.